132 related articles for article (PubMed ID: 21586891)
1. [Combination chemotherapy of docetaxel and UFT against hormone refractory prostate cancer].
Shimasaki T; Miyazawa K; Moriyama M; Tanaka T; Sato I; Nakaya N; Nakajima H; Kubo A; Suzuki K; Motoo Y
Hinyokika Kiyo; 2011 Mar; 57(3):163-6. PubMed ID: 21586891
[TBL] [Abstract][Full Text] [Related]
2. Docetaxel plus prednisolone for the treatment of metastatic hormone-refractory prostate cancer: a multicenter Phase II trial in Japan.
Naito S; Tsukamoto T; Koga H; Harabayashi T; Sumiyoshi Y; Hoshi S; Akaza H
Jpn J Clin Oncol; 2008 May; 38(5):365-72. PubMed ID: 18417502
[TBL] [Abstract][Full Text] [Related]
3. Oral combination of cyclophosphamide, uracil plus tegafur and estramustine for hormone-refractory prostate cancer.
Nishimura K; Nonomura N; Ono Y; Nozawa M; Fukui T; Harada Y; Imazu T; Takaha N; Sugao H; Miki T; Okuyama A
Oncology; 2001; 60(1):49-54. PubMed ID: 11150908
[TBL] [Abstract][Full Text] [Related]
4. A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel.
Ross RW; Beer TM; Jacobus S; Bubley GJ; Taplin ME; Ryan CW; Huang J; Oh WK;
Cancer; 2008 Feb; 112(3):521-6. PubMed ID: 18085595
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of oral uracil/tegafur plus leucovorin in patients with hormone-refractory prostate carcinoma.
Bhandari MS; Pienta KJ; Fardig J; Olson K; Smith DC
Cancer; 2006 Apr; 106(8):1715-21. PubMed ID: 16534795
[TBL] [Abstract][Full Text] [Related]
6. Docetaxel, estramustine and prednisone for hormone-refractory prostate cancer: a single-center experience.
Boehmer A; Anastasiadis AG; Feyerabend S; Nagele U; Kuczyk M; Schilling D; Corvin S; Merseburger AS; Stenzl A
Anticancer Res; 2005; 25(6C):4481-6. PubMed ID: 16334130
[TBL] [Abstract][Full Text] [Related]
7. Docetaxel, low-dose estramustine, and doxifluridine in hormone-refractory metastatic prostate cancer.
Wada Y; Kikuchi K; Takahashi W; Honda J; Nakanishi J; Matsumoto K; Kuwahara T; Kai N; Kikukawa H; Ueda S
Cancer Chemother Pharmacol; 2008 Jan; 61(1):53-61. PubMed ID: 17375305
[TBL] [Abstract][Full Text] [Related]
8. Characterization of prognostic factors and efficacy in a phase-II study with docetaxel and estramustine for advanced hormone refractory prostate cancer.
Nelius T; Reiher F; Lindenmeir T; Klatte T; Rau O; Burandt J; Filleur S; Allhoff EP
Onkologie; 2005 Nov; 28(11):573-8. PubMed ID: 16249643
[TBL] [Abstract][Full Text] [Related]
9. [Combination chemotherapy with docetaxel and cisplatin in patients with hormone-refractory prostate cancer].
Fujinami K; Miura T; Takizawa A; Osada Y
Hinyokika Kiyo; 2005 Jan; 51(1):5-8. PubMed ID: 15732332
[TBL] [Abstract][Full Text] [Related]
10. Docetaxel-prednisolone combination therapy for Japanese patients with hormone-refractory prostate cancer: a single institution experience.
Miura N; Numata K; Kusuhara Y; Shirato A; Hashine K; Sumiyoshi Y
Jpn J Clin Oncol; 2010 Nov; 40(11):1092-8. PubMed ID: 20587613
[TBL] [Abstract][Full Text] [Related]
11. Poor survival outcome of docetaxel every three weeks plus prednisone for treatment of patients with hormone-refractory metastatic prostate cancer.
El Halim Mohamed Abu Hamar A; Mansour S; El Shebiney M; El Bary NM; Sadaka E; Maria A
Hematol Oncol Stem Cell Ther; 2010; 3(3):121-7. PubMed ID: 20890069
[TBL] [Abstract][Full Text] [Related]
12. Treatment of androgen-independent, hormone-refractory prostate cancer with docetaxel in Japanese patients.
Miyoshi Y; Uemura H; Nakamura M; Hasumi H; Sugiura S; Makiyama K; Nakaigawa N; Kishida T; Ogawa T; Yao M; Kubota Y
Int J Clin Oncol; 2005 Jun; 10(3):182-6. PubMed ID: 15990966
[TBL] [Abstract][Full Text] [Related]
13. Weekly administration of docetaxel in patients with hormone-refractory prostate cancer: a pilot study on Japanese patients.
Kojima T; Shimazui T; Onozawa M; Tsukamoto S; Hinotsu S; Miyanaga N; Hattori K; Kawai K; Akaza H
Jpn J Clin Oncol; 2004 Mar; 34(3):137-41. PubMed ID: 15078909
[TBL] [Abstract][Full Text] [Related]
14. A randomized study of docetaxel and dexamethasone with low- or high-dose estramustine for patients with advanced hormone-refractory prostate cancer.
Nelius T; Klatte T; Yap R; Kalinski T; Röpke A; Filleur S; Allhoff EP
BJU Int; 2006 Sep; 98(3):580-5. PubMed ID: 16925757
[TBL] [Abstract][Full Text] [Related]
15. First- and second-line chemotherapy with docetaxel or mitoxantrone in patients with hormone-refractory prostate cancer: does sequence matter?
Michels J; Montemurro T; Murray N; Kollmannsberger C; Nguyen Chi K
Cancer; 2006 Mar; 106(5):1041-6. PubMed ID: 16456811
[TBL] [Abstract][Full Text] [Related]
16. A phase I/II dose-escalation study of exisulind and docetaxel in patients with hormone-refractory prostate cancer.
Ryan CW; Stadler WM; Vogelzang NJ
BJU Int; 2005 May; 95(7):963-8. PubMed ID: 15839914
[TBL] [Abstract][Full Text] [Related]
17. Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a phase 2 study.
Di Lorenzo G; Figg WD; Fossa SD; Mirone V; Autorino R; Longo N; Imbimbo C; Perdonà S; Giordano A; Giuliano M; Labianca R; De Placido S
Eur Urol; 2008 Nov; 54(5):1089-94. PubMed ID: 18276061
[TBL] [Abstract][Full Text] [Related]
18. Three-weekly docetaxel with prednisone is feasible for Japanese patients with hormone-refractory prostate cancer: a retrospective comparative study with weekly docetaxel alone.
Shimazui T; Kawai K; Miyanaga N; Kojima T; Sekido N; Hinotsu S; Oikawa T; Joraku A; Akaza H
Jpn J Clin Oncol; 2007 Aug; 37(8):603-8. PubMed ID: 17673473
[TBL] [Abstract][Full Text] [Related]
19. A phase II trial of docetaxel and vinorelbine in patients with hormone-refractory prostate cancer.
Goodin S; Rao KV; Kane M; Dave N; Capanna T; Doyle-Lindrud S; Engle E; Jin L; Todd M; DiPaola RS
Cancer Chemother Pharmacol; 2005 Aug; 56(2):199-204. PubMed ID: 15838657
[TBL] [Abstract][Full Text] [Related]
20. Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer.
Oudard S; Banu E; Beuzeboc P; Voog E; Dourthe LM; Hardy-Bessard AC; Linassier C; Scotté F; Banu A; Coscas Y; Guinet F; Poupon MF; Andrieu JM
J Clin Oncol; 2005 May; 23(15):3343-51. PubMed ID: 15738542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]